Business Context and Reporting Period
This Form 8-K is filed by Hancock Jaffe Laboratories, Inc. (not Envveno Medical Corp as indicated in metadata) for the reporting period ending June 12, 2018. The filing reports on the completion of the underwriters' full exercise of their over-allotment option following the Company's initial public offering (IPO).
Key Financial Metrics
- Gross Proceeds from Over-Allotment: $1,125,000
- Units Purchased in Over-Allotment: 225,000 Units
- Price per Unit: $5.00
- Total IPO Units (Initial + Over-Allotment): 1,725,000 Units
- Revenue, Profit, Cash Flow, Margins, Debt, Liquidity: The filing text does not provide a clear value for these metrics as this is a current report regarding a specific capital event, not a periodic financial statement.
Material Changes
The primary material change is the increase in capital raised through the full exercise of the underwriters' option to purchase an additional 225,000 Units on June 12, 2018. This follows the initial sale of 1,500,000 Units completed on June 4, 2018.
Guidance, Outlook, and Risks
The filing contains no management guidance, outlook, or discussion of risks and contingencies beyond the standard disclosure of the capital raise event. No unusual items were reported in this specific filing.
Investor Verification Checklist
- Verify the total gross proceeds from the IPO including the over-allotment exercise.
- Confirm the final number of shares and warrants issued to the public.
- Review the attached press release (Exhibit 99.1) for details on the use of proceeds.
- Note the discrepancy between the metadata company name (Envveno Medical Corp) and the registrant name in the filing (Hancock Jaffe Laboratories, Inc.).